Amber Therapeutics is a UK-based company specializing in implantable neuromodulation therapy for women with mixed urinary incontinence (MUI). Their lead asset, Amber-UI, utilizes the Picostim System, an adaptive neuromodulation system that can be tailored for individual patients. The company acquired this technology from Bioinduction and is focusing on addressing the condition that affects 20%-30% of chronic urinary incontinence cases.